/West%20Pharmaceutical%20Services%2C%20Inc_%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
Exton, Pennsylvania-based West Pharmaceutical Services, Inc. (WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas and internationally. The company has a market cap of $17.7 billion and is expected to release its Q1 2026 earnings soon.
Ahead of the event, analysts expect the company’s EPS to be $1.68 on a diluted basis, up 15.9% from $1.45 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.
For fiscal 2026, analysts project the company’s EPS to be $7.92, up 8.6% from $7.29 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 12.5% year over year (YoY) to $8.91 in fiscal 2027.
WST stock has grown 10.3% over the past 52 weeks, underperforming the S&P 500 Index’s ($SPX) 13.7% rise but rallying the State Street Healthcare Select Sector SPDR ETF’s (XLV) marginal decline during the same time frame.
On Feb. 13, WST stock grew 2.8% following the release of its better-than-expected Q4 2025 earnings. The company’s net sales increased 7.5% from the prior year’s quarter to $805 million, driven by strong double-digit organic growth in its High-Value Product (HVP) Components sales, which also led the company to exceed Wall Street estimates. Moreover, the company’s adjusted EPS for the quarter amounted to $7.29, also coming in on top of the Street’s estimates.
Analysts are highly bullish on WST, with the stock having a “Strong Buy” rating overall. Among the 17 analysts covering the stock, 13 are recommending a “Strong Buy,” one recommends a “Moderate Buy,” and three suggest a “Hold.” WST’s average analyst price target is $319.07, indicating an upside of 30.2% from the current levels.
